OMass Therapeutics expands Scientific Advisory Board with the appointment of Sarah Teichmann
April 08, 2024 04:00 ET
|
OMass Therapeutics
PRESS RELEASE OMass Therapeutics expands Scientific Advisory Board with the appointment of Sarah Teichmann Oxford, United Kingdom – 8th April 2024 – OMass Therapeutics (‘OMass’ or ‘the Company’), a...
OMass Therapeutics expands leadership team with the appointment of Melissa Faris as Chief Business Officer
November 15, 2023 02:00 ET
|
OMass Therapeutics
PRESS RELEASE OMass Therapeutics expands leadership team with the appointment of Melissa Faris as Chief Business Officer Oxford, United Kingdom – 15 November 2023 – OMass Therapeutics (‘OMass’ or...
OMass Therapeutics Adds Mark Namchuk, PhD to Scientific Advisory Board
September 26, 2023 02:00 ET
|
OMass Therapeutics
PRESS RELEASE OMass Therapeutics Adds Mark Namchuk, PhD to Scientific Advisory Board Oxford, United Kingdom – 26th September 2023 – OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology...
OMass Therapeutics Expands Leadership Team with Two New Appointments
August 02, 2023 02:00 ET
|
OMass Therapeutics
PRESS RELEASE OMass Therapeutics Expands Leadership Team with Two New Appointments Appointment of two senior executives in newly created rolesPeter Phillips M.D., Ph.D. joins as Senior Vice...
OMass Therapeutics Announces Appointment of New Board Chair and Series B Extension
May 15, 2023 02:00 ET
|
OMass Therapeutics
PRESS RELEASE OMass Therapeutics Announces Appointment of New Board Chairand Series B Extension Jim Geraghty joins as Independent Director and Chair, bringing US and international experience from...
OMass Therapeutics Announces New Phase of Growth with Move to New Facilities and Team Expansion to Support Portfolio Progress
April 19, 2023 02:00 ET
|
OMass Therapeutics
PRESS RELEASE OMass Therapeutics Announces New Phase of Growth with Move to New Facilities and Team Expansion to Support Portfolio Progress Move to new purpose-built 16,000ft2 flagship site on ARC...
Publication in Nature Chemistry Demonstrates the Benefits of Native Mass Spectrometry in the Interrogation of Target Ecosystems and Drug Discovery
November 10, 2022 11:00 ET
|
OMass Therapeutics
PRESS RELEASE Publication in Nature Chemistry Demonstrates the Benefits of Native Mass Spectrometry in the Interrogation of Target Ecosystems and Drug Discovery Joint publication in Nature...
OMass Therapeutics Raises $100 Million in Series B Financing to Progress Drug Pipeline in Immunology and Rare Diseases
April 28, 2022 02:00 ET
|
OMass Therapeutics
PRESS RELEASE OMass Therapeutics Raises $100 Million in Series B Financing to Progress Drug Pipeline in Immunology and Rare Diseases Financing led by new investors, GV, Northpond Ventures and Sanofi...
Publication in Nature by OMass Founder, Professor Dame Carol Robinson, Shows Power of Native Mass Spectrometry in Drug Discovery by Capturing GPCR Signalling in Native Membrane Environment
April 06, 2022 11:15 ET
|
OMass Therapeutics
PRESS RELEASE Publication in Nature by OMass Founder, Professor Dame Carol Robinson, Shows Power of Native Mass Spectrometry in Drug Discovery by Capturing GPCR Signalling in Native Membrane...
OMass Establishes Scientific Advisory Board of Leading Experts in the Use of Biophysical Approaches to Drug Discovery
March 07, 2022 04:00 ET
|
OMass Therapeutics
PRESS RELEASE OMass Establishes Scientific Advisory Board of Leading Experts in the Use of Biophysical Approaches to Drug Discovery Oxford, United Kingdom – 7 March 2022 – OMass Therapeutics...